Literature DB >> 15826838

Fusion oncogenes in tumor development.

Pierre Aman1.   

Abstract

Currently, all identified fusion oncogenes are found in rare tumor forms, and most of them only in specific tumor types. Some fusion oncogenes are frequent in healthy individuals suggesting that they rarely induce tumor growth. Multiple double-strand breaks that cluster in time and space increases the risk for formation of fusion oncogenes genes. The normal cell type specific spatial distribution of chromatin and genes in interphase nuclei may affect the risk for fusion of specific genes. Transcriptional orientation, splicing of reading frames, size and sequences of breakpoint introns are other risk factors. The biological activity of fusion oncoproteins is the most important factor for penetrance. The effects in specific target cells may explain the tumor type specificity of most fusion oncogenes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826838     DOI: 10.1016/j.semcancer.2005.01.009

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  10 in total

Review 1.  Fusion oncogenes in salivary gland tumors: molecular and clinical consequences.

Authors:  Göran Stenman
Journal:  Head Neck Pathol       Date:  2013-07-03

Review 2.  Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.

Authors:  Suneet Shukla; Zhe-Sheng Chen; Suresh V Ambudkar
Journal:  Drug Resist Updat       Date:  2012-02-09       Impact factor: 18.500

3.  The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.

Authors:  Katarina Engström; Helena Willén; Christina Kåbjörn-Gustafsson; Carola Andersson; Marita Olsson; Melker Göransson; Sofia Järnum; Anita Olofsson; Elisabeth Warnhammar; Pierre Aman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

4.  Identification and characterization of a novel group of legume-specific, Golgi apparatus-localized WRKY and Exo70 proteins from soybean.

Authors:  Yingjun Chi; Yan Yang; Guiping Li; Fei Wang; Baofang Fan; Zhixiang Chen
Journal:  J Exp Bot       Date:  2015-03-24       Impact factor: 6.992

Review 5.  Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment.

Authors:  Rudolph E Willis
Journal:  Int J Mol Sci       Date:  2016-09-14       Impact factor: 5.923

6.  FET family fusion oncoproteins target the SWI/SNF chromatin remodeling complex.

Authors:  Malin Lindén; Christer Thomsen; Pernilla Grundevik; Emma Jonasson; Daniel Andersson; Rikard Runnberg; Soheila Dolatabadi; Christoffer Vannas; Manuel Luna Santamarίa; Henrik Fagman; Anders Ståhlberg; Pierre Åman
Journal:  EMBO Rep       Date:  2019-04-08       Impact factor: 8.807

7.  FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.

Authors:  Soheila Dolatabadi; Emma Jonasson; Lisa Andersson; Manuel Luna Santamaría; Malin Lindén; Tobias Österlund; Pierre Åman; Anders Ståhlberg
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

Review 8.  Modular engineering of cellular signaling proteins and networks.

Authors:  Russell M Gordley; Lukasz J Bugaj; Wendell A Lim
Journal:  Curr Opin Struct Biol       Date:  2016-07-15       Impact factor: 6.809

9.  The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response.

Authors:  Mattias K Andersson; Anders Ståhlberg; Yvonne Arvidsson; Anita Olofsson; Henrik Semb; Göran Stenman; Ola Nilsson; Pierre Aman
Journal:  BMC Cell Biol       Date:  2008-07-11       Impact factor: 4.241

10.  Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.

Authors:  David Svec; Soheila Dolatabadi; Christer Thomsen; Nicole Cordes; Mark Shannon; Paul Fitzpatrick; Göran Landberg; Pierre Åman; Anders Ståhlberg
Journal:  Lab Invest       Date:  2018-03-27       Impact factor: 5.662

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.